Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a

Francesco Negro, Maurizio Baldi, Alessandra Mondardini, Gioacchino Leandro, Monique Chaneac, Paola Manzini, Maria Lorena Abate, Friederike Zahm, Giuseppe Dastoli, Marco Ballaré, Jean Charles Ryff, Giorgio Verme, Ferruccio Bonino

Research output: Contribution to journalArticle

Abstract

Background/Aims: Prolonged Interferon administration to patients with chronic hepatitis C, although increasing the sustained response rate, is poorly accepted and may favor drug resistance. A pulse-treatment schedule would be preferred for compliance and costs. Methods: One hundred thirty-five patients with chronic hepatitis C received 6 MU units of Interferon alfa-2a, three times weekly, continuously for 9 months (group 1: 66 patients) or for two 3-month cycles, separated by 6 months pause (group 2: 69 patients). Results: At the end of therapy, 25 of 54 patients of group 1 (46.3%) and 28 of 60 of group 2 (46.7%) had normal serum aminotransferase levels. Six months after the end of treatment, sustained responders were still similar in the two groups (11 or 16.7% vs. 7 or 10.1%; NS). A loss of response before the end of therapy was seen in 10 patients of group 1 and 6 of group 2; interferonneutralizing antibodies developed in 1 of 7 and 6 of 6 of such patients, respectively. Conclusions: The intermittent administration of interferon alfa-2a to patients with chronic hepatitis C shows a sustained response rate comparable with that achieved with continuous treatment at the same dosage. Hepatitis breakthroughs during pulse therapy appeared to be limited to interferon neutralizing antibodies, whereas a prolonged, continuous treatment is more likely to induce other forms of interferon resistance.

Original languageEnglish
Pages (from-to)479-485
Number of pages7
JournalGastroenterology
Volume107
Issue number2
Publication statusPublished - 1994

Fingerprint

Chronic Hepatitis C
Interferons
Therapeutics
interferon alfa-2a
Transaminases
Neutralizing Antibodies
Drug Resistance
Hepatitis
Compliance
Appointments and Schedules
Costs and Cost Analysis
Antibodies
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Negro, F., Baldi, M., Mondardini, A., Leandro, G., Chaneac, M., Manzini, P., ... Bonino, F. (1994). Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology, 107(2), 479-485.

Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. / Negro, Francesco; Baldi, Maurizio; Mondardini, Alessandra; Leandro, Gioacchino; Chaneac, Monique; Manzini, Paola; Abate, Maria Lorena; Zahm, Friederike; Dastoli, Giuseppe; Ballaré, Marco; Ryff, Jean Charles; Verme, Giorgio; Bonino, Ferruccio.

In: Gastroenterology, Vol. 107, No. 2, 1994, p. 479-485.

Research output: Contribution to journalArticle

Negro, F, Baldi, M, Mondardini, A, Leandro, G, Chaneac, M, Manzini, P, Abate, ML, Zahm, F, Dastoli, G, Ballaré, M, Ryff, JC, Verme, G & Bonino, F 1994, 'Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a', Gastroenterology, vol. 107, no. 2, pp. 479-485.
Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology. 1994;107(2):479-485.
Negro, Francesco ; Baldi, Maurizio ; Mondardini, Alessandra ; Leandro, Gioacchino ; Chaneac, Monique ; Manzini, Paola ; Abate, Maria Lorena ; Zahm, Friederike ; Dastoli, Giuseppe ; Ballaré, Marco ; Ryff, Jean Charles ; Verme, Giorgio ; Bonino, Ferruccio. / Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. In: Gastroenterology. 1994 ; Vol. 107, No. 2. pp. 479-485.
@article{a3e30f69c5a545d686579d9371a13d43,
title = "Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a",
abstract = "Background/Aims: Prolonged Interferon administration to patients with chronic hepatitis C, although increasing the sustained response rate, is poorly accepted and may favor drug resistance. A pulse-treatment schedule would be preferred for compliance and costs. Methods: One hundred thirty-five patients with chronic hepatitis C received 6 MU units of Interferon alfa-2a, three times weekly, continuously for 9 months (group 1: 66 patients) or for two 3-month cycles, separated by 6 months pause (group 2: 69 patients). Results: At the end of therapy, 25 of 54 patients of group 1 (46.3{\%}) and 28 of 60 of group 2 (46.7{\%}) had normal serum aminotransferase levels. Six months after the end of treatment, sustained responders were still similar in the two groups (11 or 16.7{\%} vs. 7 or 10.1{\%}; NS). A loss of response before the end of therapy was seen in 10 patients of group 1 and 6 of group 2; interferonneutralizing antibodies developed in 1 of 7 and 6 of 6 of such patients, respectively. Conclusions: The intermittent administration of interferon alfa-2a to patients with chronic hepatitis C shows a sustained response rate comparable with that achieved with continuous treatment at the same dosage. Hepatitis breakthroughs during pulse therapy appeared to be limited to interferon neutralizing antibodies, whereas a prolonged, continuous treatment is more likely to induce other forms of interferon resistance.",
author = "Francesco Negro and Maurizio Baldi and Alessandra Mondardini and Gioacchino Leandro and Monique Chaneac and Paola Manzini and Abate, {Maria Lorena} and Friederike Zahm and Giuseppe Dastoli and Marco Ballar{\'e} and Ryff, {Jean Charles} and Giorgio Verme and Ferruccio Bonino",
year = "1994",
language = "English",
volume = "107",
pages = "479--485",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a

AU - Negro, Francesco

AU - Baldi, Maurizio

AU - Mondardini, Alessandra

AU - Leandro, Gioacchino

AU - Chaneac, Monique

AU - Manzini, Paola

AU - Abate, Maria Lorena

AU - Zahm, Friederike

AU - Dastoli, Giuseppe

AU - Ballaré, Marco

AU - Ryff, Jean Charles

AU - Verme, Giorgio

AU - Bonino, Ferruccio

PY - 1994

Y1 - 1994

N2 - Background/Aims: Prolonged Interferon administration to patients with chronic hepatitis C, although increasing the sustained response rate, is poorly accepted and may favor drug resistance. A pulse-treatment schedule would be preferred for compliance and costs. Methods: One hundred thirty-five patients with chronic hepatitis C received 6 MU units of Interferon alfa-2a, three times weekly, continuously for 9 months (group 1: 66 patients) or for two 3-month cycles, separated by 6 months pause (group 2: 69 patients). Results: At the end of therapy, 25 of 54 patients of group 1 (46.3%) and 28 of 60 of group 2 (46.7%) had normal serum aminotransferase levels. Six months after the end of treatment, sustained responders were still similar in the two groups (11 or 16.7% vs. 7 or 10.1%; NS). A loss of response before the end of therapy was seen in 10 patients of group 1 and 6 of group 2; interferonneutralizing antibodies developed in 1 of 7 and 6 of 6 of such patients, respectively. Conclusions: The intermittent administration of interferon alfa-2a to patients with chronic hepatitis C shows a sustained response rate comparable with that achieved with continuous treatment at the same dosage. Hepatitis breakthroughs during pulse therapy appeared to be limited to interferon neutralizing antibodies, whereas a prolonged, continuous treatment is more likely to induce other forms of interferon resistance.

AB - Background/Aims: Prolonged Interferon administration to patients with chronic hepatitis C, although increasing the sustained response rate, is poorly accepted and may favor drug resistance. A pulse-treatment schedule would be preferred for compliance and costs. Methods: One hundred thirty-five patients with chronic hepatitis C received 6 MU units of Interferon alfa-2a, three times weekly, continuously for 9 months (group 1: 66 patients) or for two 3-month cycles, separated by 6 months pause (group 2: 69 patients). Results: At the end of therapy, 25 of 54 patients of group 1 (46.3%) and 28 of 60 of group 2 (46.7%) had normal serum aminotransferase levels. Six months after the end of treatment, sustained responders were still similar in the two groups (11 or 16.7% vs. 7 or 10.1%; NS). A loss of response before the end of therapy was seen in 10 patients of group 1 and 6 of group 2; interferonneutralizing antibodies developed in 1 of 7 and 6 of 6 of such patients, respectively. Conclusions: The intermittent administration of interferon alfa-2a to patients with chronic hepatitis C shows a sustained response rate comparable with that achieved with continuous treatment at the same dosage. Hepatitis breakthroughs during pulse therapy appeared to be limited to interferon neutralizing antibodies, whereas a prolonged, continuous treatment is more likely to induce other forms of interferon resistance.

UR - http://www.scopus.com/inward/record.url?scp=0028144718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028144718&partnerID=8YFLogxK

M3 - Article

C2 - 8039625

AN - SCOPUS:0028144718

VL - 107

SP - 479

EP - 485

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -